论文部分内容阅读
2012年8月,美国FDA批准了Roche集团旗下Genentech公司的雷尼珠单抗注射剂(ranibizumab/Lucentis)一个新适应证,即以每月(约28d)1次玻璃体内注射0.3mg(制剂规格为6mg/ml,取其0.05ml)方案治疗糖尿病患者的糖尿病性黄斑水肿所致视力损害。糖尿病性黄斑水肿是一种糖尿病相关眼并发症,会导致患者视力模糊、严重视力丧失甚至失明。糖尿病是导致美国成人失明的主要原因,糖尿病性黄斑水肿在美影响到
In August 2012, the FDA approved a new indication for ranibizumab / Lucentis from Genentech, a Roche Group company, that intravitreal injection of 0.3 mg once per month (about 28 days) 6mg / ml, whichever is 0.05ml) program for the treatment of diabetic patients with diabetic macular edema caused by visual impairment. Diabetic macular edema is a diabetic-related ocular complication that can result in blurred vision, severe vision loss, and even blindness. Diabetes is the leading cause of blindness in adults in the United States. Diabetic macular edema affects the United States